EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

PCWP/HCPWP workplan 2019-2022 and EMAN Strategy to 2025

Topic prioritisation for 2022

Presented by Ivana Silva on 22 September 2021
Public and Stakeholders Engagement

An agency of the European Union

Mandate 2019-2022 – overall objectives agreed in Sep 2019

- Continue to engage in consultations where patients', consumers' and healthcare professionals' input can bring added value to **benefit-risk assessment and decision-making**
- Contribute to EMA activities related to **information on medicines and communication with healthcare professionals and patients**
- Support the continuous improvement of the operation of the **pharmacovigilance** system
- Participate at key stages of **EMA policy development and implementation** as well as in other EMA initiatives aimed at supporting the **implementation of EU legislation**
- Contribute to recommendations as identified within the **Regulatory Science Strategy to 2025**, as relevant

Classified as public by the European Medicines Agency

PCWP/HCPWP workplan 2019-2022

Shared areas of work

- Medicines development and evaluation
- Information on medicines
- Building trust and developing methodology
- Public health focus areas

PCWP

- Patient data generation
- Package leaflet
- ADR reporting

HCPWP

- Advances in clinical practice
- Education & research

EMAN Strategy to 2025

- Availability and accessibility of medicines
- Data analytics, digital tools and digital transformation
- Innovation
- Antimicrobial resistance and other emerging health threats
- Supply chain challenges
- Sustainability of the Network and operational excellence
- COVID-19 pandemic
- EMA extended mandate

Classified as public by the European Medicines Agency

EMA multiannual workplan for 2021-2024

Strategies (EMAN and RSS to 2025)

- Develop content strategy in key public health areas and hot topics, including evidence-based communication materials
- Develop and implement a stakeholder engagement and communication plan for crisis management and EMA's extended mandate

Public health activities – stakeholder interactions

- Identify suitable experts (patients and HCPs) and support their involvement in cross-agency procedures throughout the medicine's lifecycle
- Further develop external engagement and communications to raise awareness of EMA's work and promote trust and confidence in the EU regulatory system
- Maintain and foster PCWP and HCPWP as a platform for dialogue and exchange

- We need to **take stock of** mandate 2019-2022 and **prepare for** new mandate 22-25
  - Develop PCWP/HCPWP workplan 2022-2025
- **PCWP/HCPWP journey** since 2019
  - Topics for follow up
  - Emerging topics

Classified as public by the European Medicines Agency

Medicines development and evaluation



Classified as public by the European Medicines Agency

Information on medicines

Building trust and developing methodology



Classified as public by the European Medicines Agency

Public health focus areas



Classified as public by the European Medicines Agency

Any questions?

Further information

ivana.silva@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Telephone +31 (0)88 781 6000
Send us a question Go to www.ema.europa.eu/contact

Follow us on **@EMA_News**

Classified as public by the European Medicines Agency